scispace - formally typeset
Open AccessJournal ArticleDOI

HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin.

Reads0
Chats0
TLDR
HR 756 was clearly more active than the respective reference compounds in all of these comparisons, except those involving the streptococci, and effected growth inhibition of essentially all test organisms.
Abstract
HR 756, a new parenteral cephalosporin, was compared with cefazolin and carbenicillin for activity against a total of 264 strains of Pseudomonas aeruginosa, Escherichia coli, Klebsiella spp., Proteus mirabilis, Proteus spp. (indole positive), Enterobacter spp., Salmonella typhi, Serratia marcescens, Providencia stuartii, and Staphylococcus aureus. In every comparison, except that with the last organism, HR 756 was clearly more active than cefazolin and carbenicillin. All three compounds had similar activity against penicillin-susceptible staphylococci; against penicillin-resistant strains, HR 756 and cefazolin were equally active and superior to carbenicillin. HR 756 was compared with penicillin for activity against strains of Streptococcus pyogenes, Lancefield group D streptococci, and Neisseria gonorrhoeae; with ampicillin against Haemophilus influenzae; and with cefoxitin against Bacteriodes fragilis. HR 756 was clearly more active than the respective reference compounds in all of these comparisons, except those involving the streptococci. HR 756 and penicillin were essentially equally active against S. pyogenes; against Lancefield group D, penicillin was 32 times as active as HR 756. HR 756 not only compared favorably with the reference compounds with respect to relative activity, but also effected growth inhibition of essentially all test organisms (P. aeruginosa and group D streptococci excepted) at remarkably low concentrations ranging from 0.015 to 2.0 μg/ml. A series of seven transfers of selected strains of E. coli, Klebsiella spp., S. aureus, and P. aeruginosa through medium containing HR 756 led to emergence of strains with significant levels of resistance to the agent. Resistance to HR 756 was retained for at least seven transfers through plain medium.

read more

Citations
More filters
Journal ArticleDOI

Ceftriaxone: a review of its antibacterial activity, pharmacological properties and therapeutic use

TL;DR: Cefuroxime is of value in the treatment of respiratory infections due to Haemophilus influenzae and Streptococcus pneumoniae and is useful against cephalosporin-resistant Klebsiella and Enterobacter infections and is supported by its greater activity in vivo against experimental infection in rats and mice.
Journal ArticleDOI

Cefotaxime stimulates callus growth, embryogenesis and regeneration in hexaploid bread wheat (Triticum aestivum L Em. Thell)

TL;DR: Cefotaxime significantly improved the performance of wheat in culture as measured by these characters and the potential uses for stimulating regeneration and inducing embryogenesis are discussed.
Journal ArticleDOI

Sulbactam/ampicillin: in vitro spectrum, potency, and activity in models of acute infection.

TL;DR: Sulbactam/ampicillin (1:2) was shown to be effective against ampicillin-resistant strains of Staphylococcus aureus and mixed anaerobes as discussed by the authors.
Journal ArticleDOI

Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins.

TL;DR: The desacetyl metabolite of cefotaxime (DES) is formed in vivo to a significant extent and may have considerable clinical significance, because it may accumulate in renal failure or be concentrated in the biliary tract.
References
More filters
Journal ArticleDOI

Novel Method for Detection of β-Lactamases by Using a Chromogenic Cephalosporin Substrate

TL;DR: A new cephalosporin with a highly reactive β- lactam ring was found to give an immediate color change in the presence of β-lactamases from many bacteria, including staphylococci, Bacillus species, Enterobacteriaceae, and Pseudomonas.
Journal ArticleDOI

Cefuroxime, a new cephalosporin antibiotic: activity in vitro.

TL;DR: Cefuroxime is a new broad-spectrum cephalosporin antibiotic with increased stability to β-lactamases that has the effect of widening the antibacterial spectrum of the compound so that many organisms resistant to the established cep Halosporins are susceptible to cefuroXime.
Journal ArticleDOI

Formation of Beta-Lactamase in Bacteroides fragilis: Cell-Bound and Extracellular Activity

TL;DR: Nine strains of Bacteroides fragilis were cultivated in stirred fermentors and tested for their ability to produce β-lactamase and it was shown that the enzymes were mainly cephalosporinases, which indicates that this is a new class of β-bacterial enzymes.
Journal ArticleDOI

Cefuroxime - a new cephalosporin antibiotic.

TL;DR: Cefuroxime is a new broad spectrum cephalosporin antibiotic for administration by injection that produced high, long-lasting blood levels with virtually complete recovery of unchanged antibiotic in the urine.
Journal ArticleDOI

Cefoxitin, a Semisynthetic Cephamycin Antibiotic: Antibacterial Spectrum and Resistance to Hydrolysis by Gram-Negative Beta-Lactamases

TL;DR: The in vitro activity of cefoxitin, 3-carbamolyloxymethyl-7-α-methoxy-7[2-(2-thienyl)acetamido]-3-cephem-4-carboyxlic acid, was investigated and it was highly active against gram-negative bacilli and resistance to beta-lactamase hydrolysis varied from strain to strain.
Related Papers (5)